Elliot Sigal, M.D., Ph.D.

Elliot Sigal, M.D., Ph.D.
Elliot Sigal, M.D., Ph.D.
Former Director, Executive Vice President and Chief Scientific Officer, Bristol-Myers Squibb

Dr. Elliott Sigal has over 25 years of combined experience in medicine, research and executive management. Most recently, he served as director, executive vice president and chief scientific officer and president of R&D at Bristol-Myers Squibb from 2004 until 2013. Elliott was a principal architect of the company’s successful biopharma transformation strategy, with a focus on innovative therapies for unmet medical needs, and was instrumental in increasing R&D productivity, developing the company’s strategy in biologics and acquiring external innovation in its String of Pearls initiative. Under his leadership, 14 new medicines were brought to market. Elliott previously held positions of increasing responsibility in drug discovery at the pharmaceutical company Syntex and also was vice president of R&D and chief executive officer for the genomics firm Mercator Genetics, where he provided the research leadership that resulted in the discovery of the gene for hemochromatosis, a common disorder that leads to iron overload, diabetes and liver disease.

Elliott received his M.D. from the University of Chicago and trained in internal medicine and pulmonary medicine at the University of California, San Francisco (UCSF). He received his research training at the Cardiovascular Research Institute at UCSF and served on the faculty of the UCSF department of medicine. He received his B.S., M.S. and Ph.D. in industrial engineering from Purdue University. Elliott currently serves as a member of the board of directors for the Mead Johnson Nutrition Company, the Melanoma Research Alliance and the University of California San Francisco Nina Ireland Program for Lung Health.

Independent Director

Vin Milano

Vin Milano
Chief Executive Officer, Idera Pharmaceuticals; Former President, Chief Executive Officer and Chairman, ViroPharma
Vin Milano is chief executive officer of Idera Pharmaceuticals, a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for cancers and rare diseases. Prior to Idera, Vin was president, chief executive officer and chairman of the board of directors of ViroPharma Incorporated (acquired by Shire Pharmaceuticals in January 2014), which focused on bringing innovative therapies to market for serious, unmet medical needs. ViroPharma’s lead product was Cinryze®, approved and commercially available in the United States, for the prevention of hereditary angioedema attacks and in Europe for both the treatment and prevention of hereditary angioedema attacks, a rare disease. Vin joined the company in 1996 and served as vice president, chief financial officer and treasurer from 1997 to 2006. He was instrumental in building the company, including leading efforts in raising nearly $900 million in capital, as well as the acquisitions of Lev Pharmaceuticals and the drug Vancocin from Eli Lilly. Vin played critical roles in all business development and investor relations activities for ViroPharma and contributed significantly to establishing the strategic focus of the company. Prior to joining ViroPharma, he served as senior manager at KPMG LLP, an independent registered public accounting firm. Vin received his B.S. in accounting from Rider College.
Independent Director

Anand Mehra, M.D.

Anand Mehra, M.D.
Anand Mehra, M.D.
General Partner, Sofinnova Ventures

Dr. Anand Mehra joined Sofinnova Ventures in 2007 and is focused on working with entrepreneurs to build drug development companies that have the power to improve the lives of patients. He has led the firm’s investments in Vicept Therapeutics (acquired by Allergan), Aerie Pharmaceuticals, Aclaris and Prothena, and he played a key role in the firm’s investments in SarCode (acquired by Shire), Preglem (acquired by Gedeon Richter) and Amarin. In addition to Spark Therapeutics, Anand is currently a director of Aerie and Marinus Pharmaceuticals and was on the board of Nextwave Pharmaceuticals until its acquisition by Pfizer.

Prior to joining Sofinnova, Anand worked in JP Morgan’s private equity and venture capital group, where he was heavily involved in new investments, management of their public portfolio and the firm’s spin-out from the bank. Before joining the venture community, Anand was a consultant in McKinsey & Company’s pharmaceutical practice, advising pharma and biotech on key strategic issues, and an NIH-funded fellow focused on reperfusion injury in stroke.

Anand received his M.D. from Columbia University’s College of Physicians and Surgeons and graduated Phi Beta Kappa from the University of Virginia, where he was an Echols Scholar.

Independent Director

Jeffrey Marrazzo

    Jeffrey Marrazzo
    Jeffrey D. Marrazzo
    Co-Founder and Chief Executive Officer
    Jeff Marrazzo has led the creation and growth of Spark Therapeutics from a research center within the Children's Hospital of Philadelphia to a fully integrated gene therapy company that is challenging the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable – until now. He also serves on Spark’s board of directors.

    Under Jeff's leadership, Spark has received U.S. approval for the first gene therapy in the United States. Spark has shown human proof-of-concept of Spark’s gene therapy platform in both the retina and the liver. In the four years since founding Spark, Jeff has secured more than $1 billion in capital and built an organization of more than 300 colleagues.

    During a career that has spanned the public and private sectors, Jeff has consistently championed the potential benefits of precision medicine and healthcare reform for patients. Prior to Spark, he helped build and sell the first genetic testing benefit management and pharmacogenomics medicines company to CVS Caremark. Previously, Jeff served as an advisor to former Pennsylvania Governor Edward G. Rendell, where he led reforms in the financing and delivery of healthcare.

    Jeff currently serves as a board member of the Biotechnology Innovation Organization (BIO). Jeff received a B.A. in economics and B.S.E. in systems science and engineering from the University of Pennsylvania. He also holds a dual M.B.A. / M.P.A. from The Wharton School of the University of Pennsylvania and Harvard University, a program which he founded.

    Katherine High, M.D.

    Katherine  High, M.D.
    Katherine A. High, M.D.
    Co-Founder, President and Chief Scientific Officer

    Dr. Kathy High, an accomplished hematologist with a longstanding interest in gene therapy for genetic disease, began her career studying the molecular basis of blood coagulation and the development of novel therapeutics for the treatment of bleeding disorders. Her pioneering bench-to-bedside studies of gene therapy for hemophilia led to a series of studies that characterized the human immune response to AAV vectors in a variety of target tissues. Kathy’s work has evolved to encompass clinical translation of potential genetic therapies for multiple inherited disorders.

    As the director of the Center for Cellular and Molecular Therapeutics at The Children’s Hospital of Philadelphia, Kathy assembled a multidisciplinary team of scientists and researchers working to discover new gene and cell therapies for genetic diseases and to facilitate rapid translation of preclinical discoveries into clinical application.

    Kathy was a long-time member of the faculty at the University of Pennsylvania and of the medical staff at CHOP, where she was also an Investigator of the Howard Hughes Medical Institute. She served a five-year term on the FDA Advisory Committee on Cell, Tissue and Gene Therapies and is a past president of the American Society of Gene & Cell Therapy (ASGCT). She received her A.B. in chemistry from Harvard University, an M.D. from the University of North Carolina School of Medicine, a business certification from the University of North Carolina Business School Management Institute for Hospital Administrators and an M.A. from the University of Pennsylvania.

    A. Lorris Betz, M.D., Ph.D.

      A. Lorris
      A. Lorris Betz, M.D., Ph.D.
      Senior Vice President Emeritus of Health Sciences, University of Utah
      Dr. A. Lorris Betz joined University of Utah in June 1999 as senior vice president for health sciences, dean of the School of Medicine and chief executive officer of the University of Utah Health Care. He held faculty appointments in the departments of pediatrics (professor with tenure) and neurobiology and anatomy (adjunct professor).
      During his time at the University of Utah, Lorris twice served as interim president. Following his retirement in 2012, he was named senior vice president emeritus of health sciences and was awarded an honorary doctor of science degree by the university.

      Lorris received his B.S. degree in chemistry in 1969 and M.D. and Ph.D. in biochemistry and physiology in 1975 from the University of Wisconsin, and he completed his pediatric residency and a research fellowship in pediatric neurology at the University of California, San Francisco. He joined the faculty at the University of Michigan in the departments of pediatrics and neurology in 1979 and later was appointed to the faculty in the department of surgery. Other administrative appointments at the University of Michigan included associate dean for faculty affairs, senior associate dean for academic affairs, executive associate dean and interim dean.

      Lorris’ research focused on the physiology of the blood-brain barrier and the biochemical mechanisms that lead to brain injury in stroke. He has published over 150 scientific papers and chapters. He currently serves on the board and executive committee of The Children’s Hospital of Philadelphia.
      Independent Director

      Lars Ekman, M.D., Ph.D.

      Lars Ekman, M.D., Ph.D.
      Lars Ekman, M.D., Ph.D.
      Former President of Research and Development, Elan

      Dr. Lars Ekman has 30 years of experience in senior executive, scientific and clinical functions. He has served as executive partner at Sofinnova Ventures since 2008, lending his extensive expertise in the life sciences industry to the investment team in driving new companies toward success.

      Prior to joining Sofinnova Ventures, Lars was president of research and development at Elan. He is credited with advancing Elan’s drug discovery pipeline during his tenure, and under his leadership, the company received approval for four U.S. New Drug Applications, three European Marketing Approval Applications and five Investigational New Drug Applications. These efforts advanced Elan’s immunotherapeutic approach and brought to market three neuroscience products, including Tysabri for multiple sclerosis. Prior to joining Elan, Lars was executive vice president, research and development, at Schwarz Pharma AG, and before that, held a variety of senior scientific and clinical roles at Pharmacia (now Pfizer).

      Lars is chairman of Amarin Corporation and Prothena Biosciences, executive chairman of Sophiris Bioscience, and a member of the board of directors of Ocera Therapeutics. He was co-founder and chief executive officer of Cebix, Inc. and previously served on the board of directors of InterMune (acquired by Roche) and Elan Pharmaceuticals (acquired by Perrigo).

      Lars is a board-certified surgeon with a Ph.D. in experimental biology and an M.D. from the University of Gothenburg, Sweden.

      Independent Director

      Stephen Webster

        stephan webster
        Stephen Webster
        Chief Financial Officer
        Stephen Webster has nearly 30 years of experience as a financial professional in the life sciences industry. Prior to Spark Therapeutics, Stephen was senior vice president, finance and chief financial officer at Optimer Pharmaceuticals, Inc., a commercial-stage company in the antibiotic field. Before that, he served in the same capacity at Adolor Corporation, a commercial-stage company in the gastrointestinal space. Stephen played an integral role in the sale of both Optimer and Adolor to Cubist Pharmaceuticals, Inc.

        Prior to taking his first operating role, Stephen spent 15 years as an investment banker to life sciences companies, raising more than $3 billion in financings and advising clients on more than $3 billion in aggregate mergers and acquisitions value.

        Stephen received his A.B. in economics from Dartmouth College and his M.B.A. in finance from The Wharton School of the University of Pennsylvania.

        Katherine A. High, M.D.

          Katherine A. High, M.D.
          Co-Founder, President and Chief Scientific Officer
          Dr. Kathy High, an accomplished hematologist with a longstanding interest in gene therapy for genetic disease, began her career studying the molecular basis of blood coagulation and the development of novel therapeutics for the treatment of bleeding disorders. Her pioneering bench-to-bedside studies of gene therapy for hemophilia led to a series of studies that characterized the human immune response to AAV vectors in a variety of target tissues. Kathy’s work has evolved to encompass clinical translation of potential genetic therapies for multiple inherited disorders.

          As the director of the Center for Cellular and Molecular Therapeutics at the Children’s Hospital of Philadelphia, Kathy assembled a multidisciplinary team of scientists and researchers working to discover new gene and cell therapies for genetic diseases and to facilitate rapid translation of preclinical discoveries into clinical application.

          Kathy was a long-time member of the faculty at the University of Pennsylvania and of the medical staff at CHOP, where she was also an Investigator of the Howard Hughes Medical Institute. She served a five-year term on the FDA Advisory Committee on Cell, Tissue and Gene Therapies and is a past president of the American Society of Gene & Cell Therapy (ASGCT). She received her A.B. in chemistry from Harvard University, an M.D. from the University of North Carolina School of Medicine, a business certification from the University of North Carolina Business School Management Institute for Hospital Administrators and an M.A. from the University of Pennsylvania.